CRISPR Therapeutics gets mixed analyst ratings with a $64.53 average target price amid pipeline uncertainty.

CRISPR Therapeutics received a consensus "Hold" rating from 18 analysts, with 10 recommending "Buy" and 2 "Sell." The average 1-year price target is $64.53. Positive momentum comes from strong patient starts for CASGEVY and clinical progress on CTX310, but early-stage pipeline uncertainty and recent share price weakness temper enthusiasm. The company raised $550 million through convertible notes to fund trials and commercialization. Investors await upcoming clinical data for clearer direction.